Core Viewpoint - The Baxter International, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding the safety and functionality of its Novum IQ Large Volume Pump, which reportedly has systemic defects that pose serious risks to patients [3][4]. Summary by Sections Class Action Lawsuit Details - The lawsuit is titled Electrical Workers Pension Fund, Local 103, I.B.E.W. v. Baxter International, Inc., and covers purchasers of Baxter common stock from February 23, 2022, to July 30, 2025 [1]. - Investors have until December 15, 2025, to seek appointment as lead plaintiff in the class action [1]. Allegations Against Baxter - Baxter allegedly made false or misleading statements and failed to disclose significant issues with the Novum IQ LVP, including systemic defects leading to malfunctions such as underinfusion and overinfusion [3]. - The company was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects [3]. - Baxter's attempts to address these issues were deemed inadequate, as design flaws persisted, continuing to harm patients [3]. Impact on Stock Price - Following Baxter's announcement on July 31, 2025, to pause shipments and installations of the Novum LVP, the company's stock price fell by more than 22% [4]. Lead Plaintiff Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Baxter common stock during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [5]. About Robbins Geller - Robbins Geller Rudman & Dowd LLP is a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [6].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors regarding the safety and efficacy of its Novum LVP devices, which reportedly suffered systemic defects leading to serious patient risks [3][7]. Allegation Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, exposing patients to serious injury or death [3]. - Baxter was allegedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [3]. - The company’s statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs are claimed to be materially false and misleading [3]. Next Steps - Investors who purchased Baxter shares during the class period (February 23, 2022, to July 30, 2025) and suffered losses are encouraged to contact the law firm for more information and to discuss their legal rights [4][7]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is December 15, 2025 [7]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation across various courts [5].

NEW YORK, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Baxter International Inc. (NYSE: BAX) and certain of the Company’s senior executives for securities fraud after significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Baxter, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/baxter-international-inc ...

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for allegedly misleading investors about the safety of its Novum LVP device, which has been linked to serious malfunctions and risks to patient safety [1][2]. Allegations - The complaint alleges that Baxter failed to disclose systemic defects in the Novum LVP device, which led to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [2]. - Baxter was reportedly aware of multiple malfunctions, injuries, and deaths related to the Novum LVP but did not take adequate remedial measures, leading to continued harm [2]. - The company’s statements regarding the safety, efficacy, and sales prospects of the Novum LVP were claimed to be materially false and misleading [2]. Stock Impact - Following the announcement on July 31, 2025, that Baxter would suspend all new Novum LVP sales, the company's stock price dropped by 22.4%, closing at $21.76 [3]. Next Steps for Shareholders - Shareholders interested in participating as lead plaintiffs in the class action must submit their papers by December 15, 2025 [4]. - Shareholders can remain absent class members if they choose not to participate in the case [4]. Company Background - Robbins LLP, the firm handling the class action, has been focused on shareholder rights litigation since 2002, aiming to help shareholders recover losses and improve corporate governance [5].

LOS ANGELES--(BUSINESS WIRE)--Baxter International Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – BAX. ...

Core Points - A class action lawsuit has been filed against Baxter International Inc. for alleged violations of the Securities Exchange Act of 1934 [1][4] - The lawsuit claims that Baxter made false and misleading statements regarding its supply chain issues, which were concealed from investors [4] - Investors who purchased Baxter's securities between May 25, 2022, and February 8, 2023, are encouraged to participate in the lawsuit [2] Company Information - Baxter is accused of misleading investors about its ability to maintain a strong supply chain amidst global challenges [4] - The company's projected earnings were deemed misleading, leading to investor damages once the truth was revealed [4] Legal Context - The class action lawsuit is being represented by the Schall Law Firm, which specializes in securities class action lawsuits and shareholder rights litigation [5] - Investors are advised to contact the Schall Law Firm to discuss their rights and potential participation in the lawsuit [3]

Core Viewpoint - Baxter International Inc. is facing a federal securities class action lawsuit due to allegations of making false and misleading statements regarding the safety and efficacy of its Novum LVP product, which has been linked to serious patient risks [3][4]. Group 1: Allegations and Issues - The complaint alleges that Baxter's Novum LVP suffered systemic defects leading to malfunctions such as underinfusion, overinfusion, and complete non-delivery of fluids, posing risks of serious injury or death to patients [3]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths associated with these defects but failed to adequately address the issues through customer alerts [3]. - The company's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were claimed to be materially false and misleading [3]. Group 2: Impact on Stock and Legal Proceedings - Following the announcement on July 31, 2025, that Baxter would "voluntarily and temporarily pause shipments and planned installations" of the Novum LVP, the company's stock price dropped by 22.4%, closing at $21.76 [4]. - Investors who suffered losses between February 23, 2022, and July 30, 2025, are encouraged to contact Faruqi & Faruqi, LLP to discuss their legal options, with a deadline of December 15, 2025, to seek the role of lead plaintiff in the class action [1][5].

Core Viewpoint - A class action lawsuit has been filed against Baxter International, Inc. for alleged violations of federal securities laws related to the Novum LVP device malfunctions, which posed serious risks to patients [1][2][3]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for all individuals and entities that purchased Baxter securities between February 23, 2023, and July 30, 2025 [2]. - Allegations include that Baxter misled investors by failing to disclose systemic defects in the Novum LVP, which caused malfunctions such as underinfusion and overinfusion, exposing patients to serious injury or death [3]. - Baxter was reportedly aware of multiple device malfunctions and injuries but did not take adequate remedial measures, leading to a heightened risk of customers removing the devices from service [3]. Group 2: Next Steps for Investors - Investors who suffered losses in Baxter have until December 15, 2025, to request to be appointed as lead plaintiff in the case [4]. - The law firm representing the investors operates on a contingency fee basis, meaning they will only collect fees if the case is successful [5]. Group 3: Law Firm Background - Bronstein, Gewirtz & Grossman, LLC is a nationally recognized law firm specializing in securities fraud class actions and has recovered hundreds of millions of dollars for investors [6].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Baxter International Inc. common stock between February 23, 2022, and July 30, 2025, due to alleged misleading information regarding the safety and efficacy of the Novum LVP product line [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP, which led to malfunctions that posed serious risks to patients, including underinfusion, overinfusion, and non-delivery of fluids [5]. - Baxter was reportedly aware of multiple device malfunctions, injuries, and deaths related to these defects but did not take adequate remedial measures [5]. - The lawsuit alleges that Baxter's statements regarding the safety, efficacy, product rollout, customer feedback, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Class Action Participation - Investors who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of Baxter International Inc. shareholders who purchased stock between February 23, 2022, and July 30, 2025, alleging that the company misled investors regarding the safety and efficacy of its Novum LVP devices [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Baxter failed to disclose systemic defects in the Novum LVP devices, which led to malfunctions and posed serious risks to patients [5]. - Allegations include that Baxter was aware of multiple device malfunctions, injuries, and deaths but did not take adequate remedial measures [5]. - The lawsuit asserts that Baxter's statements about the safety, efficacy, and sales prospects of the Novum LVPs were materially false and misleading [5]. Group 2: Participation Information - Shareholders who purchased Baxter common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6].